MedTrace Logo

Induction of Migraine Aura With Sildenafil

NCT02795351 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2021-11-16

No results posted yet for this study

Summary

In a double blind placebo-controlled cross-over study the effect of Sildenafil on aura and migraine headache induction is tested in patient with migraine with aura.

Conditions

  • Migraine With Aura

Interventions

DRUG

Sildenafil

Single oral administration of active or placebo one week apart

DRUG

Placebo

Sponsors & Collaborators

  • Herlev Hospital

    lead OTHER

Principal Investigators

  • Christina Kruuse, MD, DMSc · Department of Neurology, Herlev-Gentofte Hospital

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2021-02-28
Completion
2021-08-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02795351 on ClinicalTrials.gov